Thiogenesis Therapeutics (TTI.V) on Monday said it will raise up to $8 million in a non-brokered private placement of shares.
The company will place up to 16-million shares priced at $0.50 apiece.
The company expects to close the offering by the end of May subject to receipt of all necessary regulatory approvals.
Proceeds will be used to support the clinical development of TTI-0102, including an investigator-initiated study in cystinosis and a Phase 2 clinical study in Leigh syndrome, together with formulation and manufacturing activities, regulatory engagement, and general working capital and corporate needs.
The company's shares last traded May 8, closing at $0.56 on the TSX Venture Exchange.